Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Mesoblast Limited ( (AU:MSB) ) just unveiled an update.
Mesoblast Limited announced the issuance of 16,490,019 unquoted equity securities as part of an employee incentive scheme. This issuance, not intended to be quoted on the ASX, reflects the company’s ongoing efforts to incentivize employees and align their interests with the company’s growth objectives, potentially impacting its operational dynamics and stakeholder interests.
More about Mesoblast Limited
Mesoblast Limited is a company operating in the biopharmaceutical industry, focusing on developing and commercializing innovative cellular medicines. The company’s primary products are based on its proprietary mesenchymal lineage adult stem cell technology, targeting conditions such as heart failure, chronic low back pain, and inflammatory diseases, with a market focus on regenerative medicine.
YTD Price Performance: 140.91%
Average Trading Volume: 96,460
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.99B
See more data about MSB stock on TipRanks’ Stock Analysis page.
